FDA wants COVID test developers to shift from EUAs to traditional premarket pathways

The US Food and Drug Administration (FDA) has released updated guidance on COVID-19 diagnostic and serology testing, signaling its intention to review fewer emergency use authorizations (EUAs) for new tests moving forward.

Source: https://www.raps.org/news-and-articles/news-articles/2022/9/fda-wants-covid-19-test-developers-to-shift-from-e